AbbVie Hopes Imbruvica, Marivet Build Momentum Before Humira Downturn

With AbbVie's next-generation HCV combo Marivet, newly approved in Europe, the company can look to it and growing sales from Imbruvica to help make up for Humira revenue losses that may start in 2018.

Bottles

EU approval for AbbVie Inc.'s next-generation combination therapy Marivet to treat the hepatitis C virus (HCV), announced on the same day the firm reported its second quarter earnings, appears fortuitous as the new drug should offset declining revenues from the company's prior HCV product Viekira Pak and may give the firm another growth-driver alongside booming cancer drug Imbruvica.

AbbVie has a big hole to fill in the immediate future. Its anti-tumor necrosis factor agent Humira (adalimumab) has held...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.